The potential of GFAP in clinical diagnosis was proved in several multi-center studies when a GFAP and ubiquitin carboxy-terminal hydrolase L1 blood test was authorized by the FDA to be used in mild traumatic brain injury (Petzold, 2015; Wang et al., 2018; Czeiter et al., 2020; Yuh et al., 2021). This evidence concerns the gene GFAP and brain injury.